On average, they expect Solid Biosciences' stock price to reach $33.60 in the next twelve months.
Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation with our gene therapy candidate, SGT-001.Join our team of experts to advance treatments for DuchenneLearn more about how we were founded and what drives us every day.
SGT-001 has been granted Rare Pediatric Disease Designation, or RPDD, in the United States and Orphan Drug Designations in both the United States and European Union.“Patient safety is our highest priority and we plan to continue our dialogue with the FDA to determine the appropriate path for SGT-001,” said Ilan Ganot, Co-Founder, President and Chief Executive Officer of Solid Biosciences.
Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors View all Press Releases Singularly focused on Duchenne Solid Biosciences is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy (Duchenne). Shares in Solid Biosciences Inc plunged 71% on Tuesday after a trial testing its gene therapy for a muscle-wasting disorder was halted for the second time in less than two years. SGT-001 is based on pioneering research in dystrophin biology by Dr. Jeffrey Chamberlain of the University of Washington and Dr. Dongsheng Duan of the University of Missouri. This suggests a possible upside of 266.0% from the stock's current price.
“We are disappointed with the outcome today, however, we will continue to work with the FDA as we believe the clinical development of SGT-001 could offer meaningful benefits to patients with this devastating disease.” Solid Biosciences is a life sciences company focused on developing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy (Duchenne).
Letter to the Duchenne Community: Update on SGT-001 Phase I/II Clinical Hold for IGNITE DMD ProgramJoin our team of experts to advance treatments for Duchenne.© 2020 Solid Biosciences Inc. All Rights Reserved.Solid Biosciences Inc., is a Cambridge, MA-based life sciences company focused on developing transformative treatments to improve the lives of patients with Duchenne muscular dystrophy.Solid Biosciences is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne muscular dystrophy (Duchenne). Solid Biosciences Inc., is a Cambridge, MA-based life sciences company focused on developing transformative treatments to improve the lives of patients with Duchenne muscular dystrophy.
Their predictions range from $8.00 to $57.00. Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders September 5, 2019 Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update August 14, 2019 View Analyst Price Targets for Solid Biosciences. Solid Biosciences (SLDB) has reported weaker-than-expected 1Q20 results, with FY GAAP EPS of -$2.91 missing Street consensus by $0.09.